401 related articles for article (PubMed ID: 17520104)
1. Neurochemical changes associated with chronic administration of typical antipsychotics and its relationship with tardive dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Methods Find Exp Clin Pharmacol; 2007 Apr; 29(3):211-6. PubMed ID: 17520104
[TBL] [Abstract][Full Text] [Related]
2. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
Bishnoi M; Kumar A; Chopra K; Kulkarni SK
Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557
[TBL] [Abstract][Full Text] [Related]
3. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
[TBL] [Abstract][Full Text] [Related]
5. In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration.
Kulkarni SK; Bishnoi M; Chopra K
Indian J Exp Biol; 2009 Feb; 47(2):91-7. PubMed ID: 19374163
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacology; 2007; 79(3):171-83. PubMed ID: 17377417
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
[TBL] [Abstract][Full Text] [Related]
8. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
[TBL] [Abstract][Full Text] [Related]
9. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2009 Jan; 91(3):423-9. PubMed ID: 18789960
[TBL] [Abstract][Full Text] [Related]
11. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
Haleem DJ; Samad N; Haleem MA
Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
[TBL] [Abstract][Full Text] [Related]
12. Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain.
Burger ME; Fachinetto R; Zeni G; Rocha JB
Pharmacol Biochem Behav; 2005 Jul; 81(3):608-15. PubMed ID: 15953628
[TBL] [Abstract][Full Text] [Related]
13. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
Naidu PS; Kulkarni SK
Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
[TBL] [Abstract][Full Text] [Related]
14. Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors.
Bishnoi M; Chopra K; Kulkarni SK
Psychopharmacology (Berl); 2008 Feb; 196(2):243-54. PubMed ID: 17955214
[TBL] [Abstract][Full Text] [Related]
15. Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter.
Fachinetto R; Villarinho JG; Wagner C; Pereira RP; Avila DS; Burger ME; Calixto JB; Rocha JB; Ferreira J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1478-86. PubMed ID: 17669571
[TBL] [Abstract][Full Text] [Related]
16. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
17. Effects of tryptophan and valine administration on behavioral pharmacology of haloperidol.
Ali O; Haleem DJ; Saify ZS; Kamil N; Obaid R; Ahmed SW
Pak J Pharm Sci; 2005 Apr; 18(2):23-8. PubMed ID: 16431394
[TBL] [Abstract][Full Text] [Related]
18. [The behavioral and neurochemical changes in rats caused by the subchronic administration of haloperidol].
Shevchenko TP; Tolpyshev BA; Zban' LN
Eksp Klin Farmakol; 1993; 56(3):15-7. PubMed ID: 8219980
[TBL] [Abstract][Full Text] [Related]
19. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.
Naidu PS; Singh A; Kulkarni SK
Br J Pharmacol; 2002 May; 136(2):193-200. PubMed ID: 12010767
[TBL] [Abstract][Full Text] [Related]
20. Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia.
Ikram H; Samad N; Haleem DJ
Pak J Pharm Sci; 2007 Jul; 20(3):188-95. PubMed ID: 17545102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
